Business
Annual Financial Report
Physiomics PLC reported its final results for the year ended June 30, 2025, with total income increasing by 46% to £834,156. The operating loss decreased by 32% to £457,791, and the loss after taxation also decreased by 32% to £415,254. Cash and cash equivalents stood at £461,242, while the surplus of shareholders' funds was £692,171. The average total value of contract wins over FY24 and FY25 averaged over £1 million per annum, a 63% increase. The company began FY26 with approximately £594k of contracted revenue, a 19% year-on-year increase from £500k. The Board expects £60k of Grant Income will be recognised in FY26. The company raised gross proceeds of £406,417 and £500,000 through two fundraises. Disclaimer*
About this update from Physiomics Plc
[{"type":"text","content":"\n\n29 September 2025\n \nPhysiomics plc\n(\"Physiomics\" or the \"Company\")\n \nFinal Results for the year ended 30 June 2025\n \nPhysiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce its audited results for its financial year ended 30 June 2025.\n \nFinancial Highlights\n\nTotal income (revenue and grant income) increased 46% to £834,156 (2024: £570,561), meeting market expectations\nThe operating loss decreased 32% to £457,791 (2024: £670,816)\nThe loss after taxation decreased 32% to £415,254 (2024: £609,352)\nCash and cash equivalents at 30 June 2025 of £461,242 (30 June 2024: £191,072)\nAt 30 June 2025, the surplus of shareholders' funds was £692,171 (30 June 2024: £282,527)\nThe Company continues to build its pipeline with the average total value of contract wins over FY24 and FY25 averaging over £1 million per annum, a 63% increase on the yearly average of the previous five years\nThe Company started the new financial year ending 30 June 2026 (FY26) with approximately £594k of contracted revenue that is projected to be recognised within the year. This compares with approximately £500k worth of contracts carried forward from the year ended 30 June 2024 (FY24) to the year ended 30 June 2025 (FY25), a 19% year-on-year increase\nThe Board expects that £60k worth of Grant Income will be recognised in FY26 to fund the Personalised Medicine Initiative\nSuccessful completion of two fundraises (each fundraise comprising a placing and a WRAP Retail Offer), raising gross £406,417 (9 July 2024) and gross £500,000 (18 February 2025), primarily for use in funding key business growth initiatives\n\n \nOperational highlights\n\nAppointment of Head of Quantitative Pharmacology and Data Science, Dr Mark Davies in November 2024 and appointment of Head of Biometrics, Jesse Thissen commencing in July 2025\nOfficial launch of the Biometrics service line and announcement of the Company's first two Biometrics contracts worth £111k in aggregate\nExpansion of services into new therapeutic areas: 50% of projects delivered in FY25 were in therapeutic areas outside of oncology, compared to an average of 5% over the previous three years.\nDiversification of client base: 31% ...